Covid19
Conditions
Brief summary
Clinical research study that evaluates the effect of Turkish Beam-Selective UV developed by RD GLOBAL ARAŞTIRMA GELİŞTİRME SAĞLIK İLAÇ İNŞAAT YATIRIMLARI A.Ş. use into Intravascular, Intrapulmonary, Intratracial, Intrarespiratory area. Bacteria, Fungal and Virus-based pathogens systematically to collect and evaluate specific clinical performance and safety data. This Clinical Research aims to investigate the effectiveness of the treatment group and control group mortality rates, intensive care hospitalization times, monitoring the virus load by PCR, and the treatment effectiveness of UVC application. This Clinical Research covers determining the treatment effectiveness and reliability of UVC application to patient groups, the details of which are determined in the protocol.
Detailed description
DESIGN Prospective, parallel, multicentre, randomized controlled study Ages between 40 and 75 years of age and positive symptoms such as fever, malaise, cough, and shortness of breath, or positive atypical pneumonia in CT findings or COVID-19 (SARS-CoV-2) test In the intensive care unit, which is accepted as COVID 19 infection and has been treated, patients will be treated with UVC radiation and laser beam treatment according to IKU principles in addition to Antimalarial therapy + Antiviral therapy + Anitibiotic therapy. Standard treatment consisting of Antimalarial therapy + Antiviral therapy + Antibiotic therapy will be applied to the control group. The dosage of the standard treatment consisting of antimalarial therapy + Antiviral therapy + Anitibiotic therapy, the number of days of treatment, and its active ingredient are indicated in the table.
Interventions
DEVICETest Group: experimental - UVC Therapy applied
in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
Sponsors
RD Global Araştirma Geliştirme Sağlik Ilaç Inşaat Yatirimlari A.Ş.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective, Parallel, Multicenter Randomized Controlled Study Investigating
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Respiratory rate ≥ 30 * Dyspnea and breathing difficulties findings * Cases with oxygen saturation below 90% despite nasal oxygen support of 5 liters / minute and above * Cases with partial oxygen pressure below 70 mmHg despite nasal oxygen support of 5 liters / minute and above * PaO2 / FiO2 \<300 Lactate\> 4 mmol / L Bilateral infiltrations or multi-lobar involvement on chest x-ray or tomography * Hypotension (systolic blood pressure \<90 mmHg,\> 40 mmHg drop from usual SKB, mean arterial pressure \<65 mmHg) * Skin perfusion disorder Organ dysfunction such as kidney function test, liver function test disorder, thrombocytopenia, confusion Presence of immunosuppressive disease- Presence of uncontrolled comorbidity with more than one feature * Troponin height, arrhythmia * COVID 19 Test positivity
Exclusion criteria
* Under 40 years old * Pregnant women and those with suspected pregnancy * Those with a history of anaphylaxis * Those with known DNA repair deficiencies: * Those diagnosed with mental disorder, * puerperant women and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PCR Sampling | up to 15 days | viral load measurement due to covid 19, |
| Blood Tests | up to 15 days | Change from reference range in blood urea (mg/dL) |
| Radiological Imaging | up to 15 days | Radiological findings: Consolidation, ground glass appearance and reticulo-nodular opacity appearance in lung CT. |
Countries
Turkey (Türkiye)
Outcome results
None listed